Block Listing Return for the period 1 April 2016 to 30 September 2016
Name of scheme (s)
Vectura Group plc Sharesave Scheme
Vectura Group plc Long Term Incentive Plan
Vectura Group plc Unapproved Share Option Plan
Vectura Group plc Approved Share Option Plan
Innovata Option Scheme
Vectura Share Incentive Plan
Total
Balance of unallotted securities under scheme(s) at the beginning of the period
802,582
1,072,998
230,966
456,003
1,006,128
155,771
3,724,448
Plus: The amount by which block scheme(s) have been increased during the period
-
-
-
-
-
-
-
Less: Number of securities issued/allotted under scheme(s) during the period
(150,726 )
( 516,179)
(187,140)
(11,322)
-
-
( 865,367)
Equals: Balance under scheme(s) not yet issued/allotted at the end of the period
651,856
556,819
43,826
444,681
1,006,128
155,771
2,859,081
Total number of securities in issue at the end of the period (0.025p ordinary shares)
-
-
-
-
-
-
677,469,055
Enquiries:
John Murphy, Company Secretary + 44 (0)207 881 0524
Vectura Group plc published this content on 19 October 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 19 October 2016 15:23:01 UTC.
Original documenthttp://otp.investis.com/clients/uk/vectura/rns/regulatory-story.aspx?cid=301&newsid=809508
Public permalinkhttp://www.publicnow.com/view/42DD66C3423F46A98253544BCC8F54975ABCCB2A
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.